Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, In-Soo | - |
dc.contributor.author | Kim, Hyun-Jung | - |
dc.contributor.author | Kim, Tae-Hoon | - |
dc.contributor.author | Uhm, Jae-Sun | - |
dc.contributor.author | Joung, Boyoung | - |
dc.contributor.author | Lee, Moon-Hyoung | - |
dc.contributor.author | Pak, Hui-Nam | - |
dc.date.accessioned | 2021-09-02T06:42:57Z | - |
dc.date.available | 2021-09-02T06:42:57Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 0914-5087 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/73240 | - |
dc.description.abstract | Background: We evaluated the dose-dependent efficacy, safety, and all-cause mortality of non-vitamin K antagonist oral anticoagulants (NOACs) in "atrial fibrillation (AF) patients who were OAC-naive," or "AF patients with prior-stroke history" with those who were known to be high-risk subgroups under OAC. Methods: After a systematic database search (Medline, EMBASE, CENTRAL, SCOPUS, and Web of Science), five phase-III randomized trials comparing NOACs and warfarin in "OAC-naive/OAC-experienced," or "with/without prior-stroke history" subgroups were included. The outcomes were pooled using a random-effects model to determine the relative risk (RR) for stroke/systemic thromboembolism (SSTE), major bleeding, intracranial hemorrhage, and all-cause mortality. Results: 1. In OAC-naive patients, standard-dose NOACs showed superior efficacy and safety with lower mortality [RR 0.90 (0.84-0.97), p = 0.008, I-2 = 0%] compared to warfarin. 2. For OAC-experienced patients, low-dose NOACs showed equivalent efficacy but reduced risk of major bleeding [RR 0.61 (0.40-0.91), p = 0.02, I-2 = 89%], and had lower all-cause mortality [RR 0.86 (0.75-0.99), p = 0.04, I-2 = 38%] compared to warfarin. 3. For patients with prior-stroke history, low-dose NOACs showed equivalent efficacy, but reduced risk of major bleeding [RR 0.58 (0.48-0.70), p < 0.001, I-2 = 0%] and all-cause mortality [RR 0.76 (0.66-0.88), p < 0.001, I-2 = 0%] compared to warfarin. 4. Among patients without prior-stroke history, standard-dose NOAC was superior to warfarin for both SSTE prevention [RR 0.78 (0.66-0.91), p = 0.002, I-2= 43%] and all-cause mortality [RR 0.91 (0.850.97), p = 0.004, I-2 = 0%]. Conclusions: In conclusion, standard-dose NOAC showed lower all-cause mortality than warfarin in OACnaive patients with AF, and low-dose NOAC was better than warfarin among the patients with prior stroke history in terms of all-cause mortality. (C) 2018 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | TRANSIENT ISCHEMIC ATTACK | - |
dc.subject | XA NEXT-GENERATION | - |
dc.subject | AF-TIMI 48 | - |
dc.subject | PREVIOUS STROKE | - |
dc.subject | ANTIPLATELET THERAPY | - |
dc.subject | PREDICTING STROKE | - |
dc.subject | JAPANESE PATIENTS | - |
dc.subject | VS. WARFARIN | - |
dc.subject | RIVAROXABAN | - |
dc.subject | DABIGATRAN | - |
dc.title | Appropriate doses of non-vitamin K antagonist oral anticoagulants in high-risk subgroups with atrial fibrillation: Systematic review and meta-analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Hyun-Jung | - |
dc.identifier.doi | 10.1016/j.jjcc.2018.03.009 | - |
dc.identifier.scopusid | 2-s2.0-85046168697 | - |
dc.identifier.wosid | 000448491700019 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CARDIOLOGY, v.72, no.3-4, pp.284 - 291 | - |
dc.relation.isPartOf | JOURNAL OF CARDIOLOGY | - |
dc.citation.title | JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 72 | - |
dc.citation.number | 3-4 | - |
dc.citation.startPage | 284 | - |
dc.citation.endPage | 291 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | TRANSIENT ISCHEMIC ATTACK | - |
dc.subject.keywordPlus | XA NEXT-GENERATION | - |
dc.subject.keywordPlus | AF-TIMI 48 | - |
dc.subject.keywordPlus | PREVIOUS STROKE | - |
dc.subject.keywordPlus | ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | PREDICTING STROKE | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | VS. WARFARIN | - |
dc.subject.keywordPlus | RIVAROXABAN | - |
dc.subject.keywordPlus | DABIGATRAN | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Non-vitamin K antagonist oral anticoagulant | - |
dc.subject.keywordAuthor | Oral anticoagulant-nayve | - |
dc.subject.keywordAuthor | Previous stroke | - |
dc.subject.keywordAuthor | Meta-analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.